Evidence map›Paper›PMID 42445848›Full record

ArticleFrontiers in cellular and infection microbiology2026

Resistome, virulome and genomic insights into the silent dissemination of

Felipe Ramos Pinheiro, Renata Freire Alves Pereira, Giorgio Silva-Santana, André Luis Canellas, Bruno de Araújo Penna, Thiago Pavoni Gomes Chagas, Fabio Aguiar-Alves

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Felipe Ramos PinheiroLaboratory of Molecular Epidemiology and Biotechnology, School of Pharmacy, Fluminense Federal University, Niteroi, Brazil.
Renata Freire Alves PereiraLaboratory of Molecular Epidemiology and Biotechnology, School of Pharmacy, Fluminense Federal University, Niteroi, Brazil.
Giorgio Silva-SantanaDepartment of Experimental and Preclinical Development, Bio-Manguinhos, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
André Luis CanellasLaboratory of Molecular Epidemiology and Biotechnology, School of Pharmacy, Fluminense Federal University, Niteroi, Brazil.
Bruno de Araújo PennaGraduate Program in Microbiology and Parasitology, Biomedical Institute - Fluminense Federal University, Niteroi, Brazil.
Thiago Pavoni Gomes ChagasLaboratory of Molecular Epidemiology and Biotechnology, School of Pharmacy, Fluminense Federal University, Niteroi, Brazil.
Fabio Aguiar-AlvesLaboratory of Molecular Epidemiology and Biotechnology, School of Pharmacy, Fluminense Federal University, Niteroi, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This study aimed to characterize clinical Results: Among the 16 strains analyzed, 15 (93.8%) were classified as multidrug-resistant (MDR) and exhibited carbapenem resistance, being classified as carbapenem-resistant A. baumannii (CRAB). Resistance to imipenem and meropenem was observed in 93.8% (n=15) and 87.5% (n=14) of the strains, respectively. Whole-genome sequencing revealed the presence of important resistance determinants, including Discussion: Collectively, the results demonstrate the widespread dissemination of MDR/CRAB

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsCOVID-19Drug Resistance, Multiple, BacterialAnti-Bacterial AgentsBrazilGenome, BacterialHumansMicrobial Sensitivity TestsPandemicsSARS-CoV-2VirulenceVirulence FactorsWhole Genome SequencingAnti-Bacterial AgentsVirulence FactorsAcinetobacter baumanniiCOVID-19genomic surveillanceresistomevirulome

Identifiers

PMID42445848
PMCPMC13357986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.